Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 4, Pages 688
Publisher
MDPI AG
Online
2021-02-09
DOI
10.3390/cancers13040688
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal growth factor‐induced COX‐2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin‐like 4
- (2020) Kuo‐Hwa Chiang et al. CANCER SCIENCE
- Phase II Study of Low‐Dose Afatinib Maintenance Treatment Among Patients with EGFR ‐Mutated Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 ( NJLCG1601 )
- (2020) Atsushi Nakamura et al. ONCOLOGIST
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
- (2019) Barbara Burtness et al. JAMA Oncology
- Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases
- (2019) Philipp Jurmeister et al. Science Translational Medicine
- Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
- (2019) Y Guo et al. ANNALS OF ONCOLOGY
- Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
- (2018) J -P Machiels et al. ANNALS OF ONCOLOGY
- A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
- (2018) Hisashi Tanaka et al. MEDICAL ONCOLOGY
- Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)
- (2018) Akito Hata et al. CANCER
- Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
- (2016) P. M. Clement et al. ANNALS OF ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
- (2016) Jacques De Grève et al. PLoS One
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- (2015) M. Schuler et al. ANNALS OF ONCOLOGY
- Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
- (2015) Rastislav Bahleda et al. BRITISH JOURNAL OF CANCER
- A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
- (2015) J. Y. Lee et al. CLINICAL CANCER RESEARCH
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- 2014 FDA drug approvals
- (2015) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
- (2014) Brennan C Kahan et al. Trials
- A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
- (2013) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Afatinib in the treatment of head and neck squamous cell carcinoma
- (2013) Renata Ferrarotto et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A PRISMA assessment of the reporting quality of systematic reviews in orthodontics
- (2012) Padhraig S. Fleming et al. ANGLE ORTHODONTIST
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios
- (2011) Helen Barraclough et al. Journal of Thoracic Oncology
- Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
- (2011) Thomas M. Kessler et al. PLoS One
- Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
- (2009) Satoshi Shiono et al. ANNALS OF THORACIC SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now